Details

Autor(en) / Beteiligte

• Kühnen, Peter
• Argente, Jesús
• Clément, Karine
• Dollfus, Hélène
• Dubern, Béatrice
• Farooqi, Sadaf
• Groot, Corjan
• Grüters, Annette
• Holm, Jens‐Christian
• Hopkins, Mark
• Kleinendorst, Lotte
• Körner, Antje
• Meeker, David
• Rydén, Mikael
• Schnurbein, Julia
• Tschöp, Matthias
• Yeo, Giles S. H.
• Zorn, Stefanie
• Wabitsch, Martin

Titel

IMPROVE 2022 International Meeting on Pathway‐Related Obesity: Vision of Excellence

Ist Teil von

• Clinical obesity, 2024-06, Vol.14 (3), p.e12659-n/a

Ort / Verlag

Chichester, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2024

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Summary Nearly 90 clinicians and researchers from around the world attended the first IMPROVE 2022 International Meeting on Pathway‐Related Obesity. Delegates attended in person or online from across Europe, Argentina and Israel to hear the latest scientific and clinical developments in hyperphagia and severe, early‐onset obesity, and set out a vision of excellence for the future for improving the diagnosis, treatment, and care of patients with melanocortin‐4 receptor (MC4R) pathway‐related obesity. The meeting co‐chair Peter Kühnen, Charité Universitätsmedizin Berlin, Germany, indicated that change was needed with the rapidly increasing prevalence of obesity and the associated complications to improve the understanding of the underlying mechanisms and acknowledge that monogenic forms of obesity can play an important role, providing insights that can be applied to a wider group of patients with obesity. World‐leading experts presented the latest research and led discussions on the underlying science of obesity, diagnosis (including clinical and genetic approaches such as the role of defective MC4R signalling), and emerging clinical data and research with targeted pharmacological approaches. The aim of the meeting was to agree on the questions that needed to be addressed in future research and to ensure that optimised diagnostic work‐up was used with new genetic testing tools becoming available. This should aid the planning of new evidence‐based treatment strategies for the future, as explained by co‐chair Martin Wabitsch, Ulm University Medical Center, Germany.